Compare Novo Nordisk A/S (NVO) vs Raytheon Technologies Corp (RTX) Price & Performance

Novo Nordisk A/STrade

Raytheon Technologies CorpTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Raytheon Technologies Corp — how do they compare? Novo Nordisk A/S trades at $45.79 (market cap $207.85B), while Raytheon Technologies Corp trades at $223.28 (market cap $301.71B). The key difference: Raytheon Technologies Corp is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

	NVO	RTX
Market Cap	$207.85B	$301.71B
Sector	Health	Industrials
52-Week High	$63.98	$224.12
52-Week Low	$35.29	$151.75
Enterprise Value	$222.55B	$332.26B
Dividend Yield	3.81%	1.3%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

No Aura AI signal available yet.

Raytheon Technologies Corp

RTX trades at $223.86, up 0.37% today, with a bullish technical signal and strong analyst consensus of 17 buys and a $233.14 price target. Recent earnings beats and a $515 million Navy radar contract (PRNewsWire, June 3, 2026) highlight operational momentum. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.28%, though a P/E of 39.46 suggests premium valuation.

The outlook is positive, driven by defense contract wins and earnings growth, but risks include high valuation and geopolitical dependencies. Cash flow trends show strengthening operations, supporting dividend payments and strategic investments.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Novo Nordisk downgraded to Sell on weak growth and operational issues despite strong semaglutide sales.Seeking Alpha · 4 days agoBearish View details →

RTX

U.S. Army awards $472M contract to Collins Aerospace for CH-47 Chinook avionics upgradesPRNewsWire · 1 day agoBullish Raytheon wins $745M contract to produce advanced SM-3 IIA missile interceptors for U.S. and alliesPRNewsWire · 2 days agoBullish Raytheon and CET demo HADALUS, a low-cost autonomous undersea vehicle with launch capabilities.PRNewsWire · 2 days agoBullish View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Raytheon Technologies Corp

Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.